Case Study: Epana Bio evaluates 167 indications to find an optimized basket with Sleuth

Epana Bio screens 167 indications with Sleuth

Epana Bio, a nine-person biotech company, faced the high-stakes challenge of selecting which autoimmune disease indications to pursue first for its therapeutics. The traditional process was constrained by limited bandwidth, often leading to structural risk as teams could only evaluate a handful of familiar diseases. They partnered with Sleuth to overcome this challenge.

Using Sleuth, Epana Bio conducted a comprehensive evaluation of 167 indications across clinical, competitive, and commercial factors. This process narrowed the list to 25 for deeper review, then 4 for full diligence, ultimately resulting in one optimized basket of indications. The solution provided by Sleuth enabled a depth of analysis previously impossible for a small team, building conviction for this critical decision and extending into competitive intelligence and partnership preparation.

Epana Bio